Document:

Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed.  Double asterisks denote omissions.
​

Exhibit 10.2
​
Fifth Amendment
to Exclusive License Agreement
​
This Fifth Amendment to Exclusive License Agreement (the “Fifth Amendment”) is entered into by and between The Johns Hopkins University, a Maryland corporation having an address at 1812 Ashland Avenue, Suite 100, Baltimore, MD 21205 (“JHU”) and Kala Pharmaceuticals, Inc., a Delaware corporation having an address at 490 Arsenal Way, Suite 120, Watertown, MA 02472 (“Kala” or “Company”).
WHEREAS, Kala and JHU entered into an Exclusive License Agreement dated November 10, 2009 (JHU Agmt No. [**]), as amended by a first amendment (JHU Agmt. No. [**]) dated November 19, 2012 (the “First Amendment”), a second amendment (JHU Agmt. No. [**]) effective May 22, 2014 (the “Second Amendment”), a third amendment (JHU Agmt. No. [**]) effective August 26, 2014 (the “Third Amendment”), a Settlement and License Agreement between JHU, Kala and Graybug Vision, Inc. (formerly known as GrayBug, LLC and GrayBug, Inc.) (“Graybug”) that provided certain further amendments (JHU Agmt. No. [**]) effective October 24, 2014 (the “S&L Agreement”), a Side Agreement between JHU, Kala and Graybug dated October 24, 2014 (JHU Agmt. No. [**]) to further clarify the S&L Agreement  (the “Side Agreement”), and a fourth amendment (JHU Agmt. No. [**]) effective June 22, 2018 (the “Fourth Amendment”) (as so amended, the “Agreement”); and 
WHEREAS, in 2015, Graybug obtained rights in JHU Ref. [**] as a Side Patent Right through the Side Agreement as a Rights Holding Party, and such rights were deemed to be Current Patent Rights under the S&L Agreement and simultaneously granting rights to Kala as a Sublicensee Party under the S&L Agreement; and 
WHEREAS,  Graybug provided notice to JHU to terminate its  rights in the Current Patent Rights under JHU Ref. [**] and on December 6, 2017 Graybug’s rights in the Current Patent Rights under JHU Ref. [**] were terminated and pursuant to the S&L Agreement, such Graybug Current Patent Rights under JHU Ref. [**] were automatically licensed to Kala exclusively on a royalty-free, sublicensable basis, and such Patent Rights are now Kala Current Patent Rights under the Agreement; and‌
WHEREAS, pursuant to the S&L Agreement, JHU co-licensed Kala and Graybug under all the patent rights arising from JHU Ref # [**] (“Other JHU Patent Rights”), granting Kala an exclusive, sublicensable, worldwide license in the field of use of a Particle for delivery of a biologically active material through mucus, mucin, or a mucosal barrier where such delivery does not involve administration via injection to the eye (“Kala Field”), and granting Graybug an exclusive, sublicensable, worldwide license in the field of use of a particle for delivery of a biologically active material to the eye via injection, excluding any particle comprising or consisting of loteprednol etabonate (“Graybug Field”); 
WHEREAS, Graybug terminated its license under each of the Other JHU Patent Rights, such that since August 5, 2017, only Kala retains a license to each of the Other JHU Patent Rights and pursuant to Section 2(b) of the S&L Agreement, and each of the Other JHU Patent Rights becomes Kala-Licensed Other JHU Patent Right to which Kala currently has an exclusive, sublicensable, worldwide license in both the Kala Field and the Graybug Field, and Kala currently pays all patent costs associated therewith; 
WHEREAS, Kala obtained rights in JHU Ref. # [**] as NEW PATENT RIGHTS (hereinafter defined) through the Fourth Amendment to the Agreement, and such NEW PATENT RIGHTS are not subject to the S&L Agreement; and 
WHEREAS, a valuable invention entitled [**] (JHU Ref. # [**]) was developed during the course of research conducted by [**] (all hereinafter, “Inventors”), such invention to be added to the Agreement as NEW PATENT RIGHTS; and
WHEREAS, JHU has acquired through assignment all rights, title and interest, with the exception of certain retained rights by the United States Government, in said valuable invention; and
WHEREAS, Kala desires to obtain certain rights in such invention as herein provided, and to commercially 

​

​

develop, manufacture, use and distribute products and processes based upon or embodying said valuable inventions throughout the world; and
WHEREAS, the parties wish to amend the Agreement to add the invention and update the patents and patent applications listed on Exhibit D on the terms set forth herein;
​
NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth below, the parties agree as follows:
​
		1.	Terms. Capitalized terms in this Fifth Amendment shall have the same meaning as those in the Agreement, unless specifically defined in this Fifth Amendment. All section and paragraph references refer to sections or paragraphs as applicable, in the Agreement. References to the term “Agreement” in the Agreement shall be deemed to include the Fifth Amendment.

​
		2.	Effective Date. This Fifth Amendment shall be effective as of the date the last party hereto has executed this Fifth Amendment (the “Fifth Amendment Date”).

​
		3.	Agreement Second Whereas Recital. As of the Fifth Amendment Date, the second “Whereas” recital of the Agreement shall be superseded in its entirety by the following:

​
“WHEREAS, a valuable invention entitled  [**]  (JHU Ref. # [**]) was developed during the course of research conducted by [**], and a valuable invention entitled [**] (JHU Ref. # [**]) was developed during the course of research conducted by [**], and a valuable invention entitled [**] (JHU Ref. [**])  was developed during the course of research conducted by [**], and a valuable invention entitled [**] (JHU Ref. #[**]) was developed during the course of research conducted by [**], and a valuable invention entitled [**] (JHU Ref. #[**]) was developed during the course of research conducted by [**], and a valuable invention entitled [**] (JHU Ref. #[**]) was developed during the course of research conducted by [**], and a valuable invention entitled [**] (JHU Ref. #[**]) was developed during the course of research conducted by [**], and a valuable invention entitled [**] (JHU Ref. # [**]) was developed during the course of research by [**], and a valuable invention entitled [**] (JHU Ref. #[**]) was developed during the course of research conducted for Company by: [**]; and conducted for JHU by: [**], and a valuable invention entitled [**] (JHU Ref. #[**]) was developed during the course of research by [**], and a valuable invention entitled [**] (JHU Ref. # [**]) was developed during the course of research by [**] (all inventors officially affiliated with JHU hereinafter, “Inventors” ); and” 
​
		4.	Agreement Section 1.10. As of the Fifth Amendment Date, Section 1.10 of the Agreement shall be superseded in its entirety by the following:

​
“PATENT RIGHTS” shall mean the issued patents and patent applications listed in EXHIBIT D for KALA CURRENT PATENT RIGHT (JHU Ref # [**], JHU Ref # [**], JHU Ref # [**], JHU Ref # [**], JHU Ref # [**], JHU Ref # [**], JHU Ref # [**], JHU Ref # [**], JHU Ref # [**], JHU Ref # [**], JHU Ref#  [**]), and for KALA/JHU JOINTLY OWNED PATENT RIGHTS (JHU Ref # [**]), and for NEW PATENT RIGHTS (JHU Ref # [**], and JHU Ref. # [**]) (all such patent applications for JHU Ref # [**], JHU Ref # [**], JHU Ref # [**], JHU Ref # [**], JHU Ref # [**], JHU Ref # [**], JHU Ref # [**], JHU Ref # [**], JHU Ref. # [**], JHU Ref # [**], JHU Ref # [**], JHU Ref # [**],  JHU Ref # [**], and JHU Ref. # [**] hereinafter referred to as “Patent Applications”) and all continuations, divisions, claims of continuations-in-part applications directed to subject matter specifically described in the Patent Applications, continued prosecution applications and reissues, reexaminations, extensions and supplemental protection certificates thereof, and any corresponding foreign patent applications, and any patents, or other equivalent foreign patent rights issuing, granted or registered thereon. 
​
​
		5.	Agreement Section 1.15. As of the Fifth Amendment Date, Section 1.15 shall be added to the Agreement as follows:

​
1.15  “NEW PATENT RIGHTS” shall mean the patent applications and issued patents listed on EXHIBIT D for JHU Refs. # [**] and # [**] and all continuations, divisions, claims of continuations-in-part 

​

​

applications directed to subject matter specifically described in the patent applications listed on EXHIBIT D for JHU Refs. # [**] and # [**], continued prosecution applications, reissues, reexaminations, extensions and supplemental protection certificates thereof, for which the financial terms and considerations remain subject to the provisions of the Agreement and its Amendments, expressly excluding the provisions of Amendment 2 and the S&L Agreement.   
​
		6.	Amendment of Exhibit A; Change to Milestone Provision.  As of the Fifth Amendment Date, the first sentence of the paragraph at the end of Section 5 of Exhibit A of the Agreement shall be superseded in its entirety by the following:

​
Each milestone payment shall be paid for the first four (4) LICENSED PRODUCTS to achieve such milestone and no milestone payments shall be required for subsequent LICENSED PRODUCTS. For clarity, milestone payments for LICENSED PRODUCTS developed solely under NEW PATENT RIGHTS shall not be subject to the provisions of Amendment 2 and the S&L Agreement, provided however that  LICENSED PRODUCTS that are developed under a combination of KALA CURRENT PATENT RIGHTS, KALA/JHU JOINTLY OWNED PATENT RIGHTS and NEW PATENT RIGHTS shall be subject to the provisions of Amendment 2 and the S&L Agreement.  Milestone payments for the second, third and fourth LICENSED PRODUCTS shall be reduced by [**]%. 
​
		7.	Amendment of Exhibit A; Addition of Diligence Timelines for Milestones.  As of the Fifth Amendment Date, a Section 6 entitled “Diligence Timelines for Milestones for JHU Ref. [**]” shall be added to Exhibit A of the Agreement as follows:

​
“6.  Diligence Timelines for Milestones for JHU Ref. [**]. Company shall have completed the following milestones of Section 5 of Exhibit A targeting the specified time from the Fifth Amendment Date of this Agreement (each a “DILIGENCE TIMELINE”).  
​
Diligence Timelines for JHU Ref. [**]
	Achieved
	Milestone 
for JHU Ref. [**]

	[**] from the Fifth Amendment Date
	[**]

	[**] from the Fifth Amendment Date
	[**]

	[**] from the Fifth Amendment Date
	[**]

	[**] from the Fifth Amendment Date
	[**]

​
Company shall achieve the milestones as set forth above in the Diligence Timelines for JHU Ref. [**] and shall notify JHU of the achievement of each milestone within [**] of achieving them.  
(i)Extension of Diligence Timelines.  Company may request, in writing, an extension of the period for achieving a milestone set forth in the Diligence Timelines for JHU Ref. [**] by up to [**] unless the parties agree otherwise.  JHU will grant the requested extension provided (i) Company has diligently pursued achievement of the milestone; and (ii) Company remits with the request the milestone payment amount due upon achievement of the delayed milestone, if any.  The extension of a milestone shall automatically extend the deadline for subsequent milestones of the Diligence Timelines for JHU Ref. [**] respecting the same subject matter by like amount.  Company may seek extensions for a milestone no more than [**] during the term of this Agreement.
(ii)Failure to Achieve Diligence Milestone.  Failure to achieve a milestone within the timeline as set forth in the Diligence Timelines for JHU Ref. [**], with any extensions thereof, is considered a material breach of this Agreement with respect to JHU Ref. No. [**], and JHU may terminate Company’s PATENT RIGHTS with respect to JHU Ref. 

​

​

[**], upon [**] written notice,  provided that Company does not cure such breach prior to expiration of such [**] period.”
​
   ​
		8.	Amendment of Exhibit D; PATENT RIGHTS.  As of the Fifth Amendment Date, Exhibit D of the Agreement shall be superseded in its entirety by the updated Exhibit D attached hereto and shall include the following additional NEW PATENT RIGHTS and associated PATENT RIGHTS:

​
●JHU Ref. # [**], entitled, [**] (the “NEW PATENT RIGHTS”).
​
		9.	Patent Reimbursement.  In accordance with Paragraph 3.6 of the Agreement, Company will reimburse JHU for the costs of preparing, filing, maintaining and prosecuting the NEW PATENT RIGHTS added to the Agreement pursuant to this Fifth Amendment incurred prior to the Fifth Amendment Date (“Prior New Patent Costs”).  Promptly after the Fifth Amendment Date, JHU will send Company an invoice for Prior New Patent Costs, and Company will pay said invoice within [**] of Company’s receipt of the invoice.  Company will reimburse JHU, within [**] of the receipt of an invoice from JHU, for all costs incurred after the Fifth Amendment Date associated with the ongoing preparation, filing, maintenance, and prosecution of PATENT RIGHTS.

​
		10.	Amendment and License Fee.  Company shall pay to JHU, [**] dollars ($[**]) as an amendment and license fee (the “Fifth Amendment Fee”) within [**] of the Fifth Amendment Date. JHU is not required to submit an invoice for the Fifth Amendment Fee, which shall not be credited against royalties or other fees.

​
		11.	In all other respects the Agreement shall remain in full force and effect.

​
		12.	Counterparts. Signatures to this Fifth Amendment may be executed by way of facsimile or electronic signature, and such signatures shall be considered original. Signatures transmitted by email, portable document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial appearance of this Fifth Amendment shall have the same effect as the physical delivery of a paper document bearing the original signatures. All facsimile or electronic copies of this Fifth Amendment will be deemed to be duplicate originals. This Fifth Amendment may be executed simultaneously in any number of counterparts, any one of which need not contain the signature of more than one Party, but all of which shall be deemed an original and all such counterparts taken together shall constitute one and the same instrument.

​

​

​

​
IN WITNESS WHEREOF, this Fifth Amendment shall take effect as of the Fifth Amendment Date when it has been executed below by the duly authorized representatives of both parties.
​
THE JOHNS HOPKINS UNIVERSITYKALA PHARMACEUTICALS, INC.
​
​
By:    /s/ Steven L. Kousouris _________By :__/s/ Eric Trachtenberg______________
Name:  Steven L. Kousouris       Name:  Eric Trachtenberg
	Title:  Executive Director
	Title:  General Counsel, Chief Compliance Officer & Corporate Secretary

​
​
Date: _July 6, 2020____________________Date: ___July 6, 2020_________________

​Exhibit 10.3
KALA PHARMACEUTICALS, INC.
RESTRICTED STOCK UNIT AWARD
​
Kala Pharmaceuticals, Inc. (the “Company”) hereby grants the following Restricted Stock Units pursuant to its 2017 Equity Incentive Plan (the “Plan”).  The terms of the grant are set forth in the attached Restricted Stock Unit Award Agreement (the “Agreement”).  
NOTICE OF GRANT
​
Participant:[____]
​
Date of Grant:[____]
​
Number of Restricted Stock Units:[____]
​
Vesting Commencement Date: [____]
​
Vesting:[____]
​
​
All vesting is dependent on the Participant continuing to be employed by, or provide services to, the Company, as provided herein, through the relevant vesting date.   
The above is a summary description of certain provisions of the Agreement and is not intended to be complete.  In the event any aspect of this summary conflicts with the terms of the Agreement, the terms of the Agreement shall govern.
Kala Pharmaceuticals, Inc.
​
By:​ ​​ ​​ ​​ ​​ ​
Title:​ ​​ ​​ ​​ ​​ ​
​
I hereby accept the Restricted Stock Units described in the Agreement, and I agree to be bound by the terms of the Plan and the Agreement. I hereby further agree that all the decisions and determinations of the Committee shall be final and binding.
​
Participant: ​ ​​ ​​ ​​ ​​ ​
​

Date: ​ ​​ ​​ ​​ ​​ ​​ ​
​

​

​
KALA PHARMACEUTICALS, INC.
2017 EQUITY INCENTIVE PLAN
RESTRICTED STOCK UNIT AWARD AGREEMENT
This RESTRICTED STOCK UNIT AWARD AGREEMENT (the “Agreement”), dated as of date set forth on the Notice of Grant attached hereto (the “Date of Grant”), is delivered by Kala Pharmaceuticals, Inc. (the “Company”) to the individual named on the Notice of Grant attached hereto (the “Participant”).
RECITALS
A.The Kala Pharmaceuticals Inc. 2017 Equity Incentive Plan (the “Plan”) provides for the grant of stock-based awards with respect to shares of Common Stock of the Company, in accordance with the terms and conditions of the Plan. The Company has decided to make a Restricted Stock Unit award as an inducement for the Participant to promote the best interests of the Company and its stockholders.
​
B.The terms and conditions of the Restricted Stock Units should be construed and interpreted in accordance with the terms and conditions of this Agreement and the Plan. The Plan is administered and interpreted by the Compensation Committee of the Board of Directors of the Company (the “Board”) (or a subcommittee thereof), or such other committee of the Board (including, without limitation, the full Board) to which the Board has delegated power to act under or pursuant to the provisions of the Plan (the “Committee”). The Committee may delegate authority to one or more subcommittees as it deems appropriate.  If a subcommittee is appointed, all references in this Agreement to the “Committee” shall be deemed to refer to the committee. Capitalized terms that are used but not defined herein shall have the respective meanings accorded to such terms in the Plan. For purposes of this Agreement, “Company” shall mean the Company and any of its Subsidiaries where applicable.
​
NOW, THEREFORE, the parties to this Agreement, intending to be legally bound hereby, agree as follows:
1.Grant of Restricted Stock Units.  Subject to the terms and conditions set forth in this Agreement and the Plan, the Company hereby awards to the Participant the number of Restricted Stock Units (as defined in the Plan) under the Plan as set forth on the Notice of Grant attached hereto.  The Participant accepts the Restricted Stock Units and agrees to be bound by the terms and conditions of this Agreement and the Plan with respect to the award. Each vested Restricted Stock Unit entitles the Participant to receive the one share of Common Stock, as described in Paragraph 2 below.

​

​

2.Vesting of Award/Payment of Shares. 
(a)The Restricted Stock Units shall vest according to the following vesting schedule, if the Participant continues to be employed by, or provide service to, the Company (or one of its Subsidiaries) until the applicable vesting date (each, a “Vesting Date”):

	Number of Restricted Stock Units Subject to Vesting Condition
	​
​
​
​
Vesting Commencement Date
	​
Vesting Condition/Date
	% of Restricted Stock Units Subject to Condition Vested

	​
	​
	​
	​

​
(b)If and when the Restricted Stock Units vest, the Company will issue to the Participant one share of Company Common Stock for each whole Restricted Stock Unit that has vested, subject to satisfaction of the Participant’s tax withholding obligations as described in Section 5 below.  In the event that the percentage listed above would result in the vesting of partial shares, the number of Restricted Stock Units that vest on the applicable Vesting Date shall be rounded down to the nearest share. The shares of Common Stock will be issued to the Participant as soon as practicable following the Vesting Date, but in any event within 30 days of such date. The Restricted Stock Units shall cease to be outstanding upon such issuance of shares.
(c)Unless otherwise provided in a Company-sponsored plan, policy or arrangement, or any agreement to which the Company is a party, the Participant shall forfeit the unvested Restricted Stock Units in the event the Participant ceases to be employed by, or provide service to, the Company (or one of its Subsidiaries) prior to the Vesting Date. 
(d)[Notwithstanding the foregoing, upon the consummation of a Change in Control Event (as defined below) prior to a Vesting Date, the Restricted Stock Units shall immediately vest.]1 
(e)[For purposes of this Agreement a “Change in Control Event” is the occurrence of any of the following events: (i) the acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934 (the “Exchange Act”)) (a “Person”) of beneficial ownership of any capital stock of the Company if, after such acquisition, such Person beneficially owns (within the meaning of Rule 13d-3 under the Exchange Act) fifty percent (50%) or more of either (x) the then-outstanding shares of common stock of the Company (the “Outstanding Company Common Stock”) or (y) the combined voting power of the then-outstanding securities of the Company entitled to vote generally in the election of directors 

1 Include only in RSU agreement for executive officers

4

​

(the “Outstanding Company Voting Securities”); provided, however, that for purposes of this subsection (i), the following acquisitions shall not constitute a Change in Control Event: (1) any acquisition directly from the Company or (2) any acquisition by any entity pursuant to a Business Combination (as defined below) which complies with clauses (x) and (y) of subsection (iii) of this definition; or (ii) a change in the composition of the Board that results in the Continuing Directors (as defined below) no longer constituting a majority of the Board (or, if applicable, the Board of Directors of a successor corporation to the Company), where the term “Continuing Director” means at any date a member of the Board (x) who was a member of the Board on the date of the initial adoption of the Plan by the Board or (y) who was nominated or elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or election or whose election to the Board was recommended or endorsed by at least a majority of the directors who were Continuing Directors at the time of such nomination or election; provided, however, that there shall be excluded from this clause (y) any individual whose initial assumption of office occurred as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the Board; or (iii) the consummation of a merger, consolidation, reorganization, recapitalization or share exchange involving the Company, or a sale or other disposition of all or substantially all of the assets of the Company (a “Business Combination”), unless, immediately following such Business Combination, each of the following two (2) conditions is satisfied: (x) all or substantially all of the individuals and entities who were the beneficial owners of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than fifty percent (50%) of the then-outstanding shares of common stock and the combined voting power of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction owns the Company or substantially all of the Company’s assets either directly or through one (1) or more subsidiaries) (such resulting or acquiring corporation is referred to herein as the “Acquiring Corporation”) in substantially the same proportions as their ownership of the Outstanding Company Common Stock and Outstanding Company Voting Securities, respectively, immediately prior to such Business Combination and (y) no Person (excluding any employee benefit plan (or related trust) maintained or sponsored by the Company or by the Acquiring Corporation) beneficially owns, directly or indirectly, fifty percent (50%) or more of the then-outstanding shares of common stock of the Acquiring Corporation, or of the combined voting power of the then-outstanding securities of such corporation entitled to vote generally in the election of directors (except to the extent that such ownership existed prior to the Business Combination); or (iv) the liquidation or dissolution of the Company.]2

3.No Stockholder Rights Prior to Settlement; Issuance of Certificates. The Participant shall have no rights as a stockholder with respect to any shares of Common Stock represented by the Restricted Stock Units until the date of issuance of the shares of Common Stock (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), if applicable.  Except as otherwise required by the Plan, no adjustment shall be made for dividends, distributions, or other rights for which the record date is prior to the date, if any, that shares of Common Stock are issued.

2 Include only in RSU agreement for executive officers

5

​

4.Withholding. All obligations of the Company under this Agreement shall be subject to the rights of the Company as set forth in the Plan to withhold amounts required to be withheld for any taxes, if applicable. The Participant acknowledges and agrees that the Company has the right to deduct from payments of any kind otherwise due to the Participant any federal, state, local or other taxes of any kind required by law to be withheld which arise  in connection with the Participant’s Restricted Stock Units (the “Withholding Taxes”).  [ALTERNATIVE 1: Additionally, (a) the Company may, in its sole discretion, satisfy all or any portion of the Withholding Taxes obligation relating to the Participant’s Restricted Stock Units by requiring the Participant to tender a cash payment, and (b) unless otherwise determined by the Board or Committee, the Participant may elect to satisfy all or any portion of the Withholding Taxes obligation by (i) entering into a “same day sale” commitment with a broker-dealer that is a member of the Financial Industry Regulatory Authority (a “FINRA Dealer”) whereby the Participant irrevocably elects to sell a portion of the shares to be delivered under the Agreement to satisfy the Withholding Taxes and whereby the FINRA Dealer irrevocably commits to forward the proceeds necessary to satisfy the Withholding Taxes directly to the Company; or (ii) electing to have shares of Common Stock withheld by the Company from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Restricted Stock Units with a fair market value (valued in the manner determined by (or in a manner approved by) the Company) equal to the amount of such Withholding Taxes; provided, however, that the number of such shares of Common Stock so withheld shall not exceed the amount necessary to satisfy the Company’s required tax withholding obligations up to the maximum statutory withholding rates for federal, state, local and foreign tax purposes, including payroll taxes, that are applicable to supplemental taxable income.] [ALTERNATIVE 2: At such such time as the Participant is not aware of any material nonpublic information about the Company or the Common Stock and is not prohibited from doing so by the Company’s insider trading policy or otherwise, the Participant shall execute the instructions set forth in Schedule A attached hereto (the “Automatic Sale Instructions”) as the means of satisfying the Withholding Taxes. If the Participant does not execute the Automatic Sale Instructions prior to an applicable vesting date, then the Participant agrees that if under applicable law the Participant will owe taxes at such vesting date on the portion of the award then vested the Company shall be entitled to immediate payment from the Participant of the amount of any tax required to be withheld by the Company.] [ALTERNATIVE 3: The Participant acknowledges and agrees that the withholding shall be satisfied by the Company retaining from the number of shares of Common Stock otherwise issuable to the Participant on the applicable vesting date or event a number of shares of Common Stock having a fair market value (valued in the manner determined by (or in a manner approved by) the Company) equal to the amount of such Withholding Taxes; provided, however, that the number of such shares of Common Stock so withheld shall not exceed the amount necessary to satisfy the Company’s required tax withholding obligations up to the maximum statutory withholding rates for federal, state, local and foreign tax purposes, including payroll taxes, that are applicable to supplemental taxable income.]  Unless the tax withholding obligations of the Company are satisfied, the Company shall have no obligation to deliver to the Participant any Common Stock.  In the event the Company’s obligation to withhold arises prior to the delivery to the Participant of Common Stock or it is determined after the delivery of Common Stock to the Participant that the amount of the Company’s withholding obligation was greater than the amount withheld by the Company, the Participant agrees to indemnify and hold the Company harmless from any failure by the Company to withhold the proper amount. 

6

​

5.Adjustments or Reorganization Event.  The provisions of the Plan applicable to adjustments or a Reorganization Event (as described in Section 9 of the Plan) or other corporate transaction, shall apply to the Restricted Stock Units. Notwithstanding anything in the Plan to the contrary, in no event shall the Committee exercise its discretion to accelerate the payment or settlement of the Restricted Stock Units where such payment or settlement constitutes deferred compensation within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) unless, and solely to the extent that, such accelerated payment or settlement is permissible under Treasury Regulation section 1.409A-3(j)(4) or any successor provision.
6.Grant Subject to Plan Provisions.  This grant is made pursuant to the Plan, the terms of which are incorporated herein by reference, and in all respects shall be interpreted in accordance with the Plan.  The Restricted Stock Units are subject to interpretations, regulations and determinations concerning the Plan established from time to time by the Committee in accordance with the provisions of the Plan.  The Committee shall have the authority to interpret and construe the Restricted Stock Units pursuant to the terms of the Plan, and its decisions shall be conclusive as to any questions arising hereunder.
7.No Employment or Other Rights.  The grant of the Restricted Stock Units shall not confer upon the Participant any right to be retained by or in the employ or service of the Company (or any of its Subsidiaries) and shall not interfere in any way with the right of the Company (or any of its Subsidiaries) to terminate the Participant’s employment or service at any time.  The right of the Company (or any of its Subsidiaries) to terminate at will the Participant’s employment or service at any time for any reason is specifically reserved.
8.Delivery Subject to Legal Requirements. The obligation of the Company to deliver stock shall be subject to the condition that if at any time the Board shall determine in its discretion that the listing, registration or qualification of the shares upon any securities exchange or under any state or federal law, or the consent or approval of any governmental regulatory body is necessary or desirable as a condition of, or in connection with, the issue of shares, the shares may not be issued in whole or in part unless such listing, registration, qualification, consent or approval shall have been effected or obtained free of any conditions not acceptable to the Board.  The issuance of shares to the Participant pursuant to this Agreement is subject to any applicable taxes and other laws or regulations of the United States or of any state having jurisdiction thereof.
9.Clawback. In accepting the grant of Restricted Stock Units, the Participant agrees to be bound by any clawback policy that the Company may currently have in place or may adopt in the future.
10.Assignment and Transfers.  The rights and interests of the Participant under this Agreement may not be sold, assigned, encumbered or otherwise transferred except, in the event of the death of the Participant, by will or by the laws of descent and distribution.  In the event of any attempt by the Participant to alienate, assign, pledge, hypothecate, or otherwise dispose of the Restricted Stock Units or any right hereunder, or in the event of the levy or any attachment, execution or similar process upon the rights or interests hereby conferred, the Company may terminate the Restricted Stock Units by notice to the Participant, and the Restricted Stock Units and all rights hereunder shall thereupon become null and void.  The rights and protections of the Company hereunder shall extend to any successors or assigns of the Company and to the 

7

​

Company’s parents, Subsidiaries, and affiliates.  This Agreement may be assigned by the Company without the Participant’s consent.  
11.Applicable Law.  The validity, construction, interpretation and effect of this Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to the conflict of laws provisions thereof.  
12.Notice.  Any notice to the Company provided for in this Agreement shall be addressed to the Company in care of the Committee, and any notice to the Participant shall be addressed to such Participant at the current address shown on the payroll of the Company, or to such other address as the Participant may designate to the Company in writing.  Any notice shall be delivered by hand, sent by telecopy or enclosed in a properly sealed envelope addressed as stated above, deposited, postage prepaid, in a post office regularly maintained by the United States Postal Service.
13.Section 409A.  This Agreement and the Restricted Stock Units granted hereunder are intended to fit within the “short-term deferral” exemption from Section 409A of the Code, as set forth in Treasury Regulation Section 1.409A-1(b)(4) or any successor provision, or to comply with, or otherwise be exempt from, Section 409A of the Code.  This Agreement and the Restricted Stock Units shall be administered, interpreted and construed in a manner consistent with Section 409A of the Code.  Each amount payable under this Agreement is designated as a separate identified payment for purposes of Section 409A of the Code.  
14.Counterparts. This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original copy of this Agreement and all of which, when taken together, will be deemed to constitute one and the same agreement.  Facsimile or other electronic transmission of any signed original document or retransmission of any signed facsimile or other electronic transmission will be deemed the same as delivery of an original.
15.Complete Agreement.  Except as otherwise provided for herein, this Agreement and those agreements and documents expressly referred to herein embody the complete agreement and understanding among the parties and supersede and preempt any prior understandings, agreements or representations by or among the parties, written or oral, which may have related to the subject matter hereof in any way.  The terms of this Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of the Participant.
16.Committee Authority.  By entering into this Agreement the Participant agrees and acknowledges that all decisions and determinations of the Committee shall be final and binding on the Participant, his or her beneficiaries and any other person having or claiming an interest in the Award.  

​
Schedule A
Automatic Sale Instructions3 

3 To be included solely if Alternative 2 in Section 4 is selected. 

8

​

The undersigned hereby consents and agrees that any taxes due on a vesting date as a result of the vesting of Restricted Stock Units on such date shall be paid through an automatic sale of shares as follows: 
(a) Upon any vesting of Restricted Stock Units pursuant to Section 2 hereof, the Company shall arrange for the sale of such number of shares of Common Stock issuable with respect to the Restricted Stock Units that vest pursuant to Section 2 as is sufficient to generate net proceeds sufficient to satisfy the Company’s minimum statutory withholding obligations with respect to the income recognized by the Participant upon the vesting of the RSUs (based on minimum statutory withholding rates for all tax purposes, including payroll and social security taxes, that are applicable to such income), and the net proceeds of such sale shall be delivered to the Company in satisfaction of such tax withholding obligations. 
(b) The Participant hereby appoints the Chief Executive Officer, the Chief Financial Officer and the Chief Legal Officer, and any of them acting alone and with full power of substitution, to serve as his or her attorneys in fact to arrange for the sale of the Participant’s Common Stock in accordance with this Schedule A. The Participant agrees to execute and deliver such documents, instruments and certificates as may reasonably be required in connection with the sale of the shares pursuant to this Schedule A. 
(c) The Participant represents to the Company that, as of the date hereof, he or she is not aware of any material nonpublic information about the Company or the Common Stock and is not prohibited from entering into these Automatic Sale Instructions by the Company’s insider trading policy or otherwise. The Participant and the Company have structured this Agreement, including this Schedule A, to constitute a “binding contract” relating to the sale of Common Stock, consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. 
The Company shall not deliver any shares of Common Stock to the Participant until it is satisfied that all required withholdings have been made. 
 
	
	 

	
	Participant Name: ____________________________

	
	Date: ______________________________________

​

9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}]]